Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing Acute Graft-versus-host Disease After HLA-matched Transplantation

NCT07381114 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07381114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07381114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing Acute Graft-versus-host Disease After HLA-matched Transplantation
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
February 14, 2026
Completion date
December 30, 2027
Enrollment
32 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

agvhd